The Effects of Low-intensity Narrow-band Blue-light Treatment Compared to Bright White-light Treatment in Sub-syndromal Seasonal Affective Disorder
Overview
Affiliations
Background: The discovery of a novel photoreceptor in the retinal ganglion cells with a highest sensitivity of 470-490 nm blue light has led to research on the effects of short-wavelength light in humans. Several studies have explored the efficacy of monochromatic blue or blue-enriched light in the treatment of SAD. In this study, a comparison has been made between the effects of broad-wavelength light without ultraviolet (UV) wavelengths compared to narrow-band blue light in the treatment of sub-syndromal seasonal affective disorder (Sub-SAD).
Method: In a 15-day design, 48 participants suffering from Sub-SAD completed 20-minute sessions of light treatment on five consecutive days. 22 participants were given bright white-light treatment (BLT, broad-wavelength light without UV 10 000 lux, irradiance 31.7 Watt/m(2)) and 26 participants received narrow-band blue light (BLUE, 100 lux, irradiance 1.0 Watt/m(2)). All participants completed daily and weekly questionnaires concerning mood, activation, sleep quality, sleepiness and energy. Also, mood and energy levels were assessed by means of the SIGH-SAD, the primary outcome measure.
Results: On day 15, SIGH-SAD ratings were significantly lower than on day 1 (BLT 54.8 %, effect size 1.7 and BLUE 50.7 %, effect size 1.9). No statistically significant differences were found on the main outcome measures.
Conclusion: Light treatment is an effective treatment for Sub-SAD. The use of narrow-band blue-light treatment is equally effective as bright white-light treatment.
Trial Registration: This study was registered in the Dutch Trial Register (Nederlands Trial Register TC = 4342 ) (20-12-2013).
Serrage H, O Neill C, Uzunbajakava N Front Cell Infect Microbiol. 2024; 14:1307374.
PMID: 38660491 PMC: 11039841. DOI: 10.3389/fcimb.2024.1307374.
35 years of light treatment for mental disorders in the Netherlands.
Meesters Y, van Tuinen E, Gordijn M Ann Med. 2023; 55(2):2269574.
PMID: 37857364 PMC: 10588530. DOI: 10.1080/07853890.2023.2269574.
Chen I, Huang C, Huang H, Yang F, Ko K, Lee Y Int J Environ Res Public Health. 2022; 19(19).
PMID: 36231728 PMC: 9566126. DOI: 10.3390/ijerph191912430.
Oldham M, Oldham M, Desan P Psychiatr Res Clin Pract. 2022; 1(2):49-57.
PMID: 36101875 PMC: 9175704. DOI: 10.1176/appi.prcp.2019.20180011.
Szulborski K, Prosniewski M, Anjum S, Alwreikat A, Aquino P, Ramsey D Vision (Basel). 2022; 6(2).
PMID: 35737419 PMC: 9227504. DOI: 10.3390/vision6020032.